Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-trace').style.display = (document.getElementById('cakeErr681d669043303-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr681d669043303-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-code').style.display = (document.getElementById('cakeErr681d669043303-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-context').style.display = (document.getElementById('cakeErr681d669043303-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr681d669043303-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr681d669043303-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20127,
		&#039;title&#039; =&gt; &#039;Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20268,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20127,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20127,
	&#039;title&#039; =&gt; &#039;Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20268,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20127
$metaTitle = &#039;LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;
$metaKeywords = &#039;medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health&#039;
$metaDesc = &#039;
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Domestic firms rejoicing on Glivec verdict-Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br /><em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em></p><p align="justify">Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.</p><p align="justify">This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.</p><p align="justify">&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;</p><p align="justify">According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.</p><p align="justify">Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.</p><p align="justify">Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.</p><p align="justify">&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.</p><p align="justify">More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-trace').style.display = (document.getElementById('cakeErr681d669043303-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr681d669043303-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-code').style.display = (document.getElementById('cakeErr681d669043303-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-context').style.display = (document.getElementById('cakeErr681d669043303-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr681d669043303-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr681d669043303-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20127,
		&#039;title&#039; =&gt; &#039;Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20268,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20127,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20127,
	&#039;title&#039; =&gt; &#039;Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20268,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20127
$metaTitle = &#039;LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;
$metaKeywords = &#039;medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health&#039;
$metaDesc = &#039;
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Domestic firms rejoicing on Glivec verdict-Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br /><em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em></p><p align="justify">Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.</p><p align="justify">This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.</p><p align="justify">&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;</p><p align="justify">According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.</p><p align="justify">Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.</p><p align="justify">Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.</p><p align="justify">&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.</p><p align="justify">More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-trace').style.display = (document.getElementById('cakeErr681d669043303-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr681d669043303-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-code').style.display = (document.getElementById('cakeErr681d669043303-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr681d669043303-context').style.display = (document.getElementById('cakeErr681d669043303-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr681d669043303-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr681d669043303-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20127,
		&#039;title&#039; =&gt; &#039;Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20268,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20127,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20127,
	&#039;title&#039; =&gt; &#039;Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Business Standard
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20268,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20127
$metaTitle = &#039;LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey&#039;
$metaKeywords = &#039;medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health&#039;
$metaDesc = &#039;
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Business Standard&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG&#039;s patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&amp;quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &amp;quot;As for Indian companies, it will give the freedom to launch me-too products.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis&#039; Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &amp;quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&amp;quot; says an expert.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&amp;quot; says Lupin&#039;s chief financial officer Ramesh Swaminathan.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey | Im4change.org</title>
    <meta name="description" content="
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Domestic firms rejoicing on Glivec verdict-Sushmi Dey</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Business Standard</div><p align="justify"><br /><em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em></p><p align="justify">Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.</p><p align="justify">This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.</p><p align="justify">&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;</p><p align="justify">According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.</p><p align="justify">Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.</p><p align="justify">Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.</p><p align="justify">&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.</p><p align="justify">More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 20127,
		'title' => 'Domestic firms rejoicing on Glivec verdict-Sushmi Dey',
		'subheading' => '',
		'description' => '<div align="justify">
-The Business Standard
</div>
<p align="justify">
<br />
<em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em>
</p>
<p align="justify">
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
</p>
<p align="justify">
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
</p>
<p align="justify">
&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;
</p>
<p align="justify">
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
</p>
<p align="justify">
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.
</p>
<p align="justify">
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
</p>
<p align="justify">
&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.
</p>
<p align="justify">
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
</p>',
		'credit_writer' => 'The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 20268,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 20127,
	'metaTitle' => 'LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey',
	'metaKeywords' => 'medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health',
	'metaDesc' => '
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...',
	'disp' => '<div align="justify">-The Business Standard</div><p align="justify"><br /><em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em></p><p align="justify">Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.</p><p align="justify">This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.</p><p align="justify">&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;</p><p align="justify">According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.</p><p align="justify">Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.</p><p align="justify">Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.</p><p align="justify">&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.</p><p align="justify">More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 20127,
	'title' => 'Domestic firms rejoicing on Glivec verdict-Sushmi Dey',
	'subheading' => '',
	'description' => '<div align="justify">
-The Business Standard
</div>
<p align="justify">
<br />
<em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em>
</p>
<p align="justify">
Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.
</p>
<p align="justify">
This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.
</p>
<p align="justify">
&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;
</p>
<p align="justify">
According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.
</p>
<p align="justify">
Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.
</p>
<p align="justify">
Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.
</p>
<p align="justify">
&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.
</p>
<p align="justify">
More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.
</p>',
	'credit_writer' => 'The Business Standard, 3 April, 2013, http://www.business-standard.com/article/companies/domestic-firms-rejoicing-on-glivec-verdict-113040300022_1.html',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'domestic-firms-rejoicing-on-glivec-verdict-sushmi-dey-20268',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 20268,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 20127
$metaTitle = 'LATEST NEWS UPDATES | Domestic firms rejoicing on Glivec verdict-Sushmi Dey'
$metaKeywords = 'medicines,generic drugs,patents,novartis,Law and Justice,Cancer,Health'
$metaDesc = '
-The Business Standard



Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented


Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot...'
$disp = '<div align="justify">-The Business Standard</div><p align="justify"><br /><em>Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented</em></p><p align="justify">Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker.</p><p align="justify">This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented.</p><p align="justify">&quot;A patent on the new form would have given Novartis a 20-year monopoly on the drug,&quot; says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. &quot;As for Indian companies, it will give the freedom to launch me-too products.&quot;</p><p align="justify">According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge.</p><p align="justify">Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. &quot;If the patent of the drug would have been upheld, then generic companies would have suffered a major loss,&quot; says an expert.</p><p align="justify">Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country.</p><p align="justify">&quot;When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria,&quot; says Lupin's chief financial officer Ramesh Swaminathan.</p><p align="justify">More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Domestic firms rejoicing on Glivec verdict-Sushmi Dey

-The Business Standard Now, local firms can sell their low-priced generic version of the drug in India and export it to developing markets, where it is not patented Domestic drug firms such as Cipla, Natco, Ranbaxy and Hetero are a happier lot following the Supreme Court verdict on Monday, dismissing Novartis AG's patent plea for anti-cancer drug imatinib mesylate or Glivec, as sold by the Swiss drug maker. This is because the judgement allows local firms to continue selling their low-priced generic version of the drug in India as well as export it to other developing markets, where it is not patented. "A patent on the new form would have given Novartis a 20-year monopoly on the drug," says Sarabjit Kour Nangra, vice-president (research) at Angel Broking. "As for Indian companies, it will give the freedom to launch me-too products." According to industry estimates, the current generic market for the drug is around Rs 60 crore. This is exclusive of sales from Novartis' Glivec. According to Novartis, around 16,000 patients in India use Glivec, with a vast majority of them receiving it free of charge. Although the impact of the SC judgment largely remains neutral on the industry because of already existing generic penetrations, experts say it is still a major development. "If the patent of the drug would have been upheld, then generic companies would have suffered a major loss," says an expert. Going forward, multinational companies may be cautious in terms of product launches in India. However, experts say such a decision will not discourage them from launching the products given the available volumes in the country. "When it comes to matters such as this, there are many factors that are to be considered like the patient population, therapy segment in question, and patents. But no matter how one looks at it, the most important priority at the end of the day is that the man on the street is able to have access to affordable life-saving medicines; affordability and accessibility being the main criteria," says Lupin's chief financial officer Ramesh Swaminathan. More domestic drug makers are also expected to start manufacturing generic version of imatinib, increasing competition to bring down prices.